Gene · 9760
Papers2,030
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,030
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Research progress on the molecular mechanisms of PD-1 and LAG-3 synergy in regulating T cell exhaustion and immunotherapy. | Ann Med | 2026 | 41846252 | PubTator, text mining | PubMed |
| Innate-like T Cell Biology in the Tumor Microenvironment Implications for Cancer Immunotherapy. | Cells | 2026 | 41827836 | PubTator, text mining | PubMed |
| Disrupting USP14-mediated PARP1 dynamics reinstates MIC-A/B-driven antigen-independent CD8+ T cell killing in glioma. | Sci Adv | 2026 | 41824572 | PubTator, text mining | PubMed |
| Antigen-binding affinity is a key determinant of the durable antitumor activity of CD5 CAR-T cells. | Mol Ther Oncol | 2026 | 41809371 | PubTator, text mining | PubMed |
| Phenotypically similar but functionally distinct NK cell populations within the human maternal-fetal interface. | Immunohorizons | 2026 | 41808348 | PubTator, text mining | PubMed |
| Research progress on resistance mechanisms to CAR-T cell therapy in diffuse large B-cell lymphoma. | Front Oncol | 2026 | 41800035 | PubTator, text mining | PubMed |
| Balancing Intrinsic and Extrinsic Factors in CD8+ T Cell Therapy. | Immune Netw | 2026 | 41800029 | PubTator, text mining | PubMed |
| Integrating Three Functional Subsets of T Cell Immunity Into an Integrative Model for Cancer Immunotherapy. | Immune Netw | 2026 | 41800028 | PubTator, text mining | PubMed |
| Tumor Cells as Architects of Immune Refractoriness: Dismantling Intrinsic Programs of Tumor Cells for Clinical Translation. | Immune Netw | 2026 | 41800027 | PubTator, text mining | PubMed |
Active Macropinocytosis, Lipid Catabolism, and Exhausting Immune Microenvironment of Ascites Tumor Cells Are Involved in Resistance to Platinum-Based Therapy in Patients With High-Grade Serous Ovarian Cancer. | MedComm (2020) | 2026 | 41799929 | PubTator, text mining | PubMed |
| Multimodal tumor thermal therapy enhances antitumor immunity by expanding tumor-reactive CX3CR1⁺GPR56⁺ T cells in hepatocellular carcinoma. | Theranostics | 2026 | 41799205 | PubTator, text mining | PubMed |
| Neoadjuvant chemotherapy-induced immune remodeling in ovarian cancer: implications for TIL dynamics and combination immunotherapy. | Front Immunol | 2026 | 41798957 | PubTator, text mining | PubMed |
| Ubiquitin E3 ligase KLHL6 brings exhausted T-cells back into action. | Immun Inflamm | 2026 | 41797878 | PubTator, text mining | PubMed |
| Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignancies. | Front Immunol | 2026 | 41789096 | PubTator, text mining | PubMed |
| PD-1 genetic fate mapping uncovers immune cell diversity mediating the efficacy of combined PD-1 blockade and chemotherapy. | Oncoimmunology | 2026 | 41787604 | PubTator, text mining | PubMed |
| Multi-view deep learning of highly multiplexed imaging data improves association of cell states with clinical outcomes. | Bioinform Adv | 2026 | 41782683 | PubTator, text mining | PubMed |
| Single-cell multi-omics analysis of the tumour microenvironment for colorectal cancer liver metastasis. | Clin Transl Med | 2026 | 41781365 | PubTator, text mining | PubMed |
| Immune Exhaustion in Chronic Infection and Cancer: Signaling Pathways and Therapeutic Interventions. | MedComm (2020) | 2026 | 41768369 | PubTator, text mining | PubMed |
| Extensive evolution and T cell escape by SARS-CoV-2 in a 2.5-year persistent infection of an immunocompromised host. | iScience | 2026 | 41767267 | PubTator, text mining | PubMed |
| Reprogramming the immunosuppressive breast cancer microenvironment: integrating cellular, metabolic, and stromal targets for rational immunotherapy. | Front Immunol | 2026 | 41766877 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9760/papers?page=4